Neurocrine Biosciences (NBIX) Gains from Investment Securities (2016 - 2021)
Historic Gains from Investment Securities for Neurocrine Biosciences (NBIX) over the last 12 years, with Q4 2021 value amounting to $1.8 million.
- Neurocrine Biosciences' Gains from Investment Securities fell 8593.75% to $1.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was $23.4 million, marking a year-over-year increase of 8281.25%. This contributed to the annual value of $271.6 million for FY2024, which is 3525.9% up from last year.
- According to the latest figures from Q4 2021, Neurocrine Biosciences' Gains from Investment Securities is $1.8 million, which was down 8593.75% from $5.6 million recorded in Q2 2021.
- Over the past 5 years, Neurocrine Biosciences' Gains from Investment Securities peaked at $76.6 million during Q4 2019, and registered a low of $100000.0 during Q3 2019.
- Moreover, its 5-year median value for Gains from Investment Securities was $1.3 million (2017), whereas its average is $13.0 million.
- In the last 5 years, Neurocrine Biosciences' Gains from Investment Securities tumbled by 9033.51% in 2018 and then skyrocketed by 123310.13% in 2019.
- Neurocrine Biosciences' Gains from Investment Securities (Quarter) stood at $59.5 million in 2017, then crashed by 90.34% to $5.7 million in 2018, then skyrocketed by 1233.1% to $76.6 million in 2019, then plummeted by 83.29% to $12.8 million in 2020, then crashed by 85.94% to $1.8 million in 2021.
- Its Gains from Investment Securities was $1.8 million in Q4 2021, compared to $5.6 million in Q2 2021 and $16.0 million in Q1 2021.